The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Ratain, Mark J.
One or more keywords matched the following items that are connected to Ratain, Mark J.
Item TypeName
Concept Antibodies, Monoclonal, Humanized
Academic Article A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Academic Article A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
Academic Article Vascular endothelial growth factor pathway.
Academic Article A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
Academic Article Unsupported off-label chemotherapy in metastatic colon cancer.
Academic Article Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
Academic Article Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
Academic Article Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
Academic Article Alternative dosing regimens for atezolizumab: right dose, wrong frequency.
Academic Article Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Letter.
Academic Article Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
Academic Article Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19.
Academic Article COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
Academic Article Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
Academic Article Dose Optimization of Pembrolizumab: Less May Be More.
Academic Article Subcutaneous Atezolizumab: A Jab Without a Benefit.
Academic Article In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
Academic Article Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
Search Criteria
  • Antibodies Monoclonal Humanized